ABVD

Last updated

ABVD is a chemotherapy regimen used in the first-line treatment of Hodgkin lymphoma, replacing the older MOPP protocol. It consists of concurrent treatment with the chemotherapy drugs:

Contents

Medical uses

As of 2007, ABVD is widely used as the initial chemotherapy treatment for newly diagnosed Hodgkin lymphoma.[ citation needed ] It has been the most effective and least toxic chemotherapy regimen available for treating early-stage Hodgkin Lymphoma. [1] The other chemotherapy regimens that are widely used in this setting is the Stanford V and BEACOPP regimens.[ citation needed ]

Administration

One cycle of ABVD chemotherapy is typically given over 4 weeks in two doses, with the first on day 1 and the second dose on day 15. All four of the chemotherapy drugs are given intravenously. ABVD chemotherapy is usually given in the outpatient setting — that is, it does not require hospitalization.[ citation needed ]

Typical dosages for one 28-day cycle of ABVD are:

DrugDoseModeDays
Adriamycin 25  mg/m2IV bolusDays 1 and 15
Bleomycin 10  IU/m2IV bolusDays 1 and 15
Vinblastine 6 mg/m2IV bolusDays 1 and 15
Dacarbazine 375 mg/m2IV infusionDays 1 and 15

Dosages above are given according to the body surface area dosing model.

The number of cycles given depends upon the stage of the disease and how well the patient tolerates chemotherapy. Doses may be delayed because of neutropenia, thrombocytopenia, or other side effects.[ citation needed ]

A FDG PET scan is commonly advised following the completion of ABVD to assess response to the therapy. Interim PET (following 2 cycles) may be useful in aiding prognostication, but does not yet guide changes in therapy except within clinical trial protocols. [2]

Side effects

Side effects of ABVD can be divided into acute (those occurring while receiving chemotherapy) and delayed (those occurring months to years after completion of chemotherapy). Delayed side effects have assumed particular importance because many patients treated for Hodgkin lymphoma are cured and can expect long lives after completion of chemotherapy.[ citation needed ]

Acute side effects

Delayed side effects

Supportive care

Supportive care refers to efforts to prevent or treat side effects of ABVD chemotherapy, and to help people get through the chemotherapy with the least possible discomfort.

Antiemetics

Significant advances in antiemetic, or anti-nausea, medications have been made in the beginning of the 21st century. Patients will often receive a combination of 5-HT3 receptor antagonists (e.g. ondansetron), corticosteroids, and benzodiazepines before chemotherapy to prevent nausea. These medicines are also effective after nausea develops, as are phenothiazines. Each person's sensitivity to nausea and vomiting varies. Overall, while patients often experience some mild to moderate nausea, severe nausea or vomiting are uncommon with ABVD.

Emetogenicity is high. eviQ has recommendations for preventing nausea and vomiting. [10]

Ensure that patients have sufficient antiemetics for breakthrough emesis with Metoclopramide 10 mg to 20 mg every 4 to 6 hours when necessary OR Prochlorperazine 10 mg PO or 12.5 mg IV every 4 to 6 hours when necessary. [11]

Growth factors

Blood growth factors are medicines that stimulate the bone marrow to produce more of a certain kind of blood cell. Commonly used examples include G-CSF and erythropoietin. These drugs are sometimes used with ABVD to prevent neutropenia (low white blood cell count) and anemia related to the chemotherapy, although their use is not universal.

History

Prior to the mid-1960s, advanced-stage Hodgkin disease was treated with single-agent chemotherapy, with fairly dismal long-term survival and cure rates. With advances in the understanding of chemotherapy resistance and the development of combination chemotherapy, Vincent T. DeVita and George Canellos at the National Cancer Institute (United States) developed the MOPP regimen. This combination of mechlorethamine, vincristine (Oncovin), procarbazine, and prednisone proved capable of curing almost 70% of patients with advanced-stage Hodgkin lymphoma. [12] [13]

While MOPP was remarkably successful in curing advanced Hodgkin lymphoma, its toxicity remained significant. Aside from bone marrow suppression, frequent side effects included nerve injury caused by vincristine and allergic reactions to procarbazine. Long-term effects were also a concern, as patients were often cured and could expect long survival after chemotherapy. Infertility was a major long-term side effect, and even more seriously, the risk of developing treatment-related myelodysplasia or acute leukemia was increased up to 14-fold in patients who received MOPP. [14] These treatment-related hematological malignancies peaked at 5 to 9 years after treatment for Hodgkin's lymphoma, and were associated with a dismally poor prognosis.[ citation needed ]

Development

Therefore, alternative regimens were tested in an attempt to avoid alkylating agents (such as mechlorethamine), which were thought to be responsible for many of the long-term side effects of MOPP. ABVD was developed as a potentially less toxic and more effective alternative to MOPP; the initial results of ABVD were published in an Italian thesis. [15] The results were published in English in 1975 by an Italian group led by Gianni Bonadonna. [16] A number of trials then compared MOPP vs. MOPP plus ABVD [17] and compared ABVD to previous and other regimens for Hodgkin lymphoma. A large trial by CALGB suggested that ABVD was superior to MOPP, with a higher rate of overall response, less hematologic toxicity, better relapse-free survival, and better outcomes after relapse in the patients treated with ABVD. [18] Later studies confirmed the superiority of ABVD in terms of effectiveness, and also demonstrated that late side effects, such as treatment-related acute leukemia, were less common with ABVD as compared to MOPP. [4] Taken together, these results led ABVD to the replacement of MOPP with ABVD in the first-line treatment of Hodgkin lymphoma. A number of trials then compared ABVD or ABVD-like or hybrid MOPP/ABVD to BEACOPP and escalated BEACOPP regimens.[ citation needed ]

Research

Fertility

Scientists analyzed samples of ovarian tissue donated by eight women who had undergone ABVD chemotherapy, alongside tissue from fifteen healthy women.[ citation needed ]

They found that the tissue from the cancer patients treated with ABVD had between four and 10 times more eggs compared with tissue from women who had received a different chemotherapy, or healthy women of a similar age. The ovarian tissue was in healthy condition, appearing similar to tissue from young women's ovaries.[ citation needed ]

Although the eggs are in an immature state, the scientists are trying to discover how they were created, then work out a way to bring them to maturity. It is unclear if the eggs in their current form would be functional. [19]

See also

Related Research Articles

<span class="mw-page-title-main">Chemotherapy</span> Treatment of cancer using drugs that inhibit cell division or kill cells

Chemotherapy is a type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. Chemotherapy may be given with a curative intent or it may aim to prolong life or to reduce symptoms. Chemotherapy is one of the major categories of the medical discipline specifically devoted to pharmacotherapy for cancer, which is called medical oncology.

<span class="mw-page-title-main">Lymphoma</span> Hematologic cancer that affects lymphocytes

Lymphoma is a group of blood and lymph tumors that develop from lymphocytes. The name typically refers to just the cancerous versions rather than all such tumours. Signs and symptoms may include enlarged lymph nodes, fever, drenching sweats, unintended weight loss, itching, and constantly feeling tired. The enlarged lymph nodes are usually painless. The sweats are most common at night.

<span class="mw-page-title-main">Nabilone</span> Synthetic cannabinoid

Nabilone, sold under the brand name Cesamet among others, is a synthetic cannabinoid with therapeutic use as an antiemetic and as an adjunct analgesic for neuropathic pain. It mimics tetrahydrocannabinol (THC), the primary psychoactive compound found naturally occurring in Cannabis.

<span class="mw-page-title-main">Cyclophosphamide</span> Medication used as chemotherapy and to suppress the immune system

Cyclophosphamide (CP), also known as cytophosphane among other names, is a medication used as chemotherapy and to suppress the immune system. As chemotherapy it is used to treat lymphoma, multiple myeloma, leukemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma. As an immune suppressor it is used in nephrotic syndrome, granulomatosis with polyangiitis, and following organ transplant, among other conditions. It is taken by mouth or injection into a vein.

<span class="mw-page-title-main">History of cancer chemotherapy</span>

The era of cancer chemotherapy began in the 1940s with the first use of nitrogen mustards and folic acid antagonist drugs. The targeted therapy revolution has arrived, but many of the principles and limitations of chemotherapy discovered by the early researchers still apply.

<span class="mw-page-title-main">Anthracycline</span> Class of antibiotics

Anthracyclines are a class of drugs used in cancer chemotherapy that are extracted from Streptomyces bacterium. These compounds are used to treat many cancers, including leukemias, lymphomas, breast, stomach, uterine, ovarian, bladder cancer, and lung cancers. The first anthracycline discovered was daunorubicin, which is produced naturally by Streptomyces peucetius, a species of Actinomycetota. Clinically the most important anthracyclines are doxorubicin, daunorubicin, epirubicin and idarubicin.

<span class="mw-page-title-main">Epirubicin</span> Chemical compound

Epirubicin is an anthracycline drug used for chemotherapy. It can be used in combination with other medications to treat breast cancer in patients who have had surgery to remove the tumor. It is marketed by Pfizer under the trade name Ellence in the US and Pharmorubicin or Epirubicin Ebewe elsewhere.

<span class="mw-page-title-main">Procarbazine</span> A chemotherapy medication used for several cancer types

Procarbazine is a chemotherapy medication used for the treatment of Hodgkin's lymphoma and brain cancers. For Hodgkin's it is often used together with chlormethine, vincristine, and prednisone while for brain cancers such as glioblastoma multiforme it is used with lomustine and vincristine. It is typically taken by mouth.

<span class="mw-page-title-main">Vinblastine</span> Chemical compound; chemotherapy medication

Vinblastine (VBL), sold under the brand name Velban among others, is a chemotherapy medication, typically used with other medications, to treat a number of types of cancer. This includes Hodgkin's lymphoma, non-small-cell lung cancer, bladder cancer, brain cancer, melanoma, and testicular cancer. It is given by injection into a vein.

MOPP is a combination chemotherapy regimen used to treat Hodgkin lymphoma. The acronym is derived from the component drugs of the regimen:

<span class="mw-page-title-main">Dacarbazine</span> Chemotherapy medication

Dacarbazine, also known as imidazole carboxamide and sold under the brand name DTIC-Dome, is a chemotherapy medication used in the treatment of melanoma and Hodgkin's lymphoma. For Hodgkin's lymphoma it is often used together with vinblastine, bleomycin, and doxorubicin. It is given by injection into a vein.

CHOP is the acronym for a chemotherapy regimen used in the treatment of non-Hodgkin lymphoma. CHOP consists of:

Adjuvant therapy, also known as adjunct therapy, adjuvant care, or augmentation therapy, is a therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. The surgeries and complex treatment regimens used in cancer therapy have led the term to be used mainly to describe adjuvant cancer treatments. An example of such adjuvant therapy is the additional treatment usually given after surgery where all detectable disease has been removed, but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery, then further treatment is not technically adjuvant.

A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via cytotoxicity.

Stanford V, is a chemotherapy regimen intended as a first-line treatment for Hodgkin lymphoma. The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens such as ABVD. The chemical agents used are:

BEACOPP is a chemotherapy regimen for treatment of Hodgkin lymphoma developed by the German Hodgkin Study Group used for patients in Stages > II or early with unfavorable risk factors. Patients typically receive treatment in cycles of 21 days with no drugs given on days 15–21. There also exists a more intensive regimen with cycles of 14 days. Usually a course of BEACOPP therapy consists of four, sometimes six to eight cycles, or in combination with ABVD. In some countries BEACOPP still is experimental, in others it is a standard therapy. In the United States, ABVD is generally given instead, because BEACOPP is perceived by practicing oncologists to have the potential to induce more secondary neoplasias. However, the final results from the GHSG HD14 trial indicate that "there were no overall differences in treatment-related mortality or secondary malignancies" of BEACOPP relative to ABVD.

<span class="mw-page-title-main">Nodular lymphocyte predominant Hodgkin lymphoma</span> Medical condition

Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a slow-growing CD20 positive form of Hodgkin lymphoma, a cancer of the immune system's B cells.

Brentuximab vedotin, sold under the brand name Adcetris, is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL. The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seagen in the US.

Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes debilitating symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.

High-dose chemotherapy and bone marrow transplant (HDC/BMT), also high-dose chemotherapy with autologous bone marrow transplant, was an ineffective treatment regimen for metastatic breast cancer, and later high-risk breast cancer, that was considered promising during the 1980s and 1990s. With an overall idea that more is better, this process involved taking cells from the person's bone marrow to store in a lab, then to give such high doses of chemotherapy drugs that the remaining bone marrow was destroyed, and then to inject the cells taken earlier back into the body as replacement. It was ultimately determined to be no more effective than normal treatment, and to have significantly higher side effects, including treatment-related death.

References

  1. "Chemotherapy and Drug Treatment". Leukemia & Lymphoma Society.
  2. Aldin A, Umlauff L, Estcourt LJ, Collins G, Moons KG, Engert A, et al. (January 2020). Cochrane Haematology Group (ed.). "Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies". The Cochrane Database of Systematic Reviews. 1 (8): CD012643. doi:10.1002/14651858.CD012643.pub3. PMC   6984446 . PMID   31930780.
  3. del Pino BM (Feb 23, 2010). "Chemotherapy-induced Peripheral Neuropathy". NCI Cancer Bulletin. 7 (4): 6. Archived from the original on 2011-12-11.
  4. 1 2 3 Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, et al. (January 1987). "Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy". Journal of Clinical Oncology. 5 (1): 27–37. doi:10.1200/JCO.1987.5.1.27. PMID   2433409.
  5. Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G (May 1985). "Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD". European Journal of Cancer & Clinical Oncology. 21 (5): 601–5. doi:10.1016/0277-5379(85)90088-4. PMID   2408897.
  6. Anselmo AP, Cartoni C, Bellantuono P, Maurizi-Enrici R, Aboulkair N, Ermini M (1990). "Risk of infertility in patients with Hodgkin's disease treated with ABVD vs MOPP vs ABVD/MOPP". Haematologica. 75 (2): 155–8. PMID   1694156.
  7. Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM (October 2005). "Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma". Journal of Clinical Oncology. 23 (30): 7614–20. doi: 10.1200/JCO.2005.02.7243 . PMID   16186594.
  8. Canellos GP, Duggan D, Johnson J, Niedzwiecki D (April 2004). "How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?". Journal of Clinical Oncology. 22 (8): 1532–3. doi: 10.1200/JCO.2004.99.010 . PMID   15084636.
  9. van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, et al. (February 2000). "Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood". Journal of Clinical Oncology. 18 (3): 487–97. doi:10.1200/JCO.2000.18.3.487. PMID   10653864.
  10. "7-Prevention of anti-cancer therapy induced nausea and vomiting (AINV) | eviQ".
  11. "56-Advanced stage ABVD (DOXOrubicin bleomycin vinBLASTine dacarbazine) | eviQ".
  12. DeVita VT, Simon RM, Hubbard SM, Young RC, Berard CW, Moxley JH, et al. (May 1980). "Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute". Annals of Internal Medicine. 92 (5): 587–95. doi:10.7326/0003-4819-92-5-587. PMID   6892984.
  13. Longo DL, Young RC, Wesley M, Hubbard SM, Duffey PL, Jaffe ES, DeVita VT (September 1986). "Twenty years of MOPP therapy for Hodgkin's disease". Journal of Clinical Oncology. 4 (9): 1295–306. doi:10.1200/JCO.1986.4.9.1295. PMID   3528400. S2CID   32719728.
  14. Kaldor JM, Day NE, Clarke EA, Van Leeuwen FE, Henry-Amar M, Fiorentino MV, et al. (January 1990). "Leukemia following Hodgkin's disease". The New England Journal of Medicine. 322 (1): 7–13. doi: 10.1056/NEJM199001043220102 . PMID   2403650.
  15. Università degli Studi di Milano,Facoltà di Medicina e Chirurgia, ( anno accademico : 1974/75 ) in : 'Studio comparativo di due schemi di polichemioterapia negli stadi avanzati della Malattia di Hodgkin', (relatore prof. Fasoli Angelo . ), tesi di laurea di Fossati Vittorio, Matr. 81.606, (thesis of a student led by Bonadonna Gianni)
  16. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C (July 1975). "Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP". Cancer. 36 (1): 252–9. doi:10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7. PMID   54209. S2CID   23133131.
  17. Bonadonna, G.; Fossati, V.; De Lena, M. (1978). "MOPP versus MOPP plus ABVD in Stage IV Hodgkin's disease". Proc. Am. Assoc. Cancer Res.-ASCO. 19: 363.
  18. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. (November 1992). "Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD". The New England Journal of Medicine. 327 (21): 1478–84. doi: 10.1056/NEJM199211193272102 . PMID   1383821.
  19. McLaughlin M, Kelsey TW, Wallace WH, Anderson RA, Telfer EE (January 2017). "Non-growing follicle density is increased following adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy in the adult human ovary". Human Reproduction. 32 (1): 165–174. doi: 10.1093/humrep/dew260 . hdl: 10023/12263 . PMID   27923859.